New Cardio Safe Initiative Aims to Advance Safer, More Respectful Clinical Care Environments
ACC’s new Cardio Safe initiative, launching this fall, will help cardiologists and cardiovascular professionals address patient- and visitor-initiated mistreatment while fostering safer, more respectful and psychologically secure clinical care environments.
Editors’ Corner | Mother Nature Does Not Offer a Free Lunch!
It takes longer than we’d like to gain confidence in new percutaneous technology. Twenty years after Andreas Grüntzig’s first coronary PTCA, we were still debating whether stents were good or bad. Now we’re wondering about a return to balloons alone – albeit drug-coated. So it has been with left atrial appendage occlusion (LAAO).
Cover Story | Stroke Prevention in AFib: Defining the Role of LAAO
Left atrial appendage occlusion (LAAO) has become the most performed structural heart procedure in the U.S., with an estimated >700,000 procedures completed to date and volumes climbing sharply every year.
Feature | New Science From ESC Congress 2026
The ACC was live from ESC Congress 2026 in Munich, bringing members the latest cardiovascular science and clinical guidance. Below are standout studies in heart failure (HF), structural heart disease, dyslipidemia and prevention, and more, plus promising news in pulmonary embolism (PE).
Feature | POTS: Recognition Is Rising, But Management Gaps Remain
For many patients with postural orthostatic tachycardia syndrome (POTS), a form of dysautonomia, simply standing can trigger palpitations, dizziness, fatigue and exercise intolerance.
Feature | MedAxiom at 25: A Quarter Century Helping Cardiovascular Organizations Thrive
Twenty-five years ago, cardiovascular leaders faced a very different landscape. Independent cardiology practices were flourishing, fee-for-service reimbursement dominated, and consolidation, digital transformation and payment reform had yet to reshape the specialty.
ACCEL Lite: PRESC1SE-MI: Efficacy of the ESC 0/1-hour Pathway
In this episode, Jeroen J. Bax PhD, MD, FACC and Jasper Boeddinghaus, MD discuss “PRESC1SE-MI: Safety and efficacy of the ESC 0/1-hour Pathwayâ€.
Statins For the Prevention of Anthracycline-Induced Cardiotoxicity: Contextualizing Guideline Recommendations For Clinical Practice
Anthracycline-induced cardiotoxicity is a major contributor to long-term cardiovascular (CV) outcomes in survivors of cancer. Up to 20% of patients exposed to anthracyclines develop irreversible cardiomyopathy through mechanisms leading to cardiomyocyte death.
PAD Series Spotlights Current Burden, Future Challenges
A three-part series published Sept. 22 in The Lancet underscores the growing global impact of peripheral artery disease (PAD) and reinforces the need for earlier diagnosis, improved treatment and better access to care.
Atenolol Associated With Lower MACE Risk After MI Than Bisoprolol
Among patients without recorded heart failure (HF), starting atenolol after a myocardial infarction (MI) was associated with a lower two-year risk of major adverse cardiovascular events (MACE), but not all-cause mortality, compared with bisoprolol, according to an observational cohort study published Sept. 22 in NEJM Evidence.
